Welcome to our dedicated page for Lyra Therapeutics SEC filings (Ticker: LYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lyra Therapeutics, Inc. filings document the company's transition from a Nasdaq-listed clinical-stage biotechnology issuer toward delisting, deregistration and wind-down disclosures. Form 25 and Form 15 filings address removal of Lyra common stock from Nasdaq listing and registration, along with termination or suspension of Exchange Act reporting obligations for the covered security.
Lyra's recent Form 8-K reports cover exit and disposal activities, suspension of further LYR-210 development, workforce and executive-employment changes, lease and sublease terminations, payment obligations, notices of default, continued-listing matters, and related capital-structure and governance disclosures.
Lyra Therapeutics, Inc. reported an insider tax-related share sale by its President & CEO, Maria Palasis. On 01/06/2026, she sold 1,702 shares of Lyra common stock at a price of $3.364 per share. The filing states that these shares were sold to cover taxes due upon the vesting of restricted stock units, under a mandatory Rule 10b5-1 trading instruction adopted on January 1, 2025. After this transaction, she beneficially owned 1,096,733 shares of Lyra common stock directly.
Lyra Therapeutics (LYRA): insider transactions reported. Perceptive-affiliated entities disclosed multiple open-market sales of common stock on 11/11/2025, 11/12/2025, and 11/13/2025. Reported weighted average prices were $4.3146, $4.0594, and $3.9001, respectively.
Following these transactions, the filing shows Perceptive Life Sciences Master Fund, Ltd. with 124,859 shares and Perceptive LS (A), LLC with 14,026 shares, each held indirectly. The filing notes that prices reflect weighted averages over multiple trades and that the reporting persons disclaim beneficial ownership beyond their indirect pecuniary interests.
Lyra Therapeutics (LYRA) filed its Q3 2025 10‑Q, reporting a narrower quarter but ongoing strain. Collaboration revenue was $25 thousand, while operating expenses fell to $6.3 million, reflecting prior restructuring. The company posted a net loss of $6.0 million for the quarter and $22.0 million year‑to‑date.
Cash and cash equivalents were $22.1 million as of September 30, 2025, down from $40.6 million at year‑end. Total assets were $43.7 million and stockholders’ deficit was $4.3 million, compared with equity of $11.6 million at December 31, 2024. Net cash used in operations was $22.8 million for the nine months ended September 30, 2025.
Management disclosed “substantial doubt” about the company’s ability to continue as a going concern. Lyra received a Nasdaq notice in August 2025 for not meeting the $2.5 million stockholders’ equity requirement; Nasdaq accepted a plan with a deadline of December 31, 2025. The company effected a 1‑for‑50 reverse stock split on May 27, 2025 and completed a June 2025 financing for $5.0 million gross. Shares outstanding were 1,774,882 as of November 7, 2025.
Lyra Therapeutics (LYRA): Director-affiliated entities reported sales of common stock. A Form 4 shows multiple sales on 11/06/2025, 11/07/2025, and 11/10/2025 at weighted average prices of $5.1799, $4.7467, and $4.5398, respectively. The transactions were reported as indirect holdings tied to Perceptive Life Sciences Master Fund, Ltd. and Perceptive LS (A), LLC.
Following these transactions, beneficially owned shares reported were 166,101 for the Master Fund and 18,659 for Perceptive LS. Footnotes note prices are weighted averages with individual trade prices available upon request. Reporting persons include Perceptive Advisors, LLC, Perceptive LS GP, LLC, and Joseph Edelman, who is listed as a director and reports indirect ownership as described.
Lyra Therapeutics insider amendment corrects previously reported stock-option activity and clarifies current holdings. The reporting person, Maria Palasis, was originally granted performance stock options totaling 11,000 shares (stated as 550,000 pre-split) on 03/21/2024, but those PSOs were forfeited for no value on 02/14/2025. An earlier Form 4 filed on 10/03/2025 mistakenly reported the acquisition of 3,667 PSOs; this amended Form 4/A, filed on 10/08/2025, reverses that entry and states the Reporting Person currently does not beneficially own any of the PSOs granted on 03/21/2024. The filing was signed by an attorney-in-fact and notes the transaction price of the related employee stock option as $303.5 with an expiration of 03/20/2034.
Maria Palasis, President & CEO and a director of Lyra Therapeutics, Inc. (LYRA), reported a change in beneficial ownership after the company determined on 10/01/2025 that Milestone 2 under a performance stock option (PSO) award was achieved. The PSO grant, originally made on 03/21/2024, covered up to 11,000 shares; 3,667 PSOs were earned as a result of Milestone 2. Those earned PSOs are exercisable under the award terms and will vest on 01/31/2028. Following the reported transaction, the filing shows 7,333 shares of common stock beneficially owned directly by the reporting person. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Palasis and dated 10/03/2025.
Lyra Therapeutics, Inc. filed a report noting that on September 4, 2025 it posted a new corporate presentation on its website. Company representatives may use this presentation in discussions with investors, analysts, and other interested parties.
The presentation is provided as Exhibit 99.1 to the report and is incorporated by reference, giving stakeholders a centralized source for updated company information. Lyra’s common stock trades on the Nasdaq Capital Market under the symbol LYRA.
Lyra Therapeutics reported receipt of a Nasdaq deficiency letter because its stockholders' equity was approximately $1.6 million as of June 30, 2025, below the Nasdaq Capital Market minimum requirement of $2.5 million. The filing states the deficiency letter has no immediate effect on the listing or trading of the company's common stock, which will continue to trade on Nasdaq under the symbol LYRA. The company points investors to its Annual Report and Quarterly Report for risk disclosures and reiterates standard forward-looking statements caution. The report is dated August 22, 2025, and signed by CFO Jason Cavalier.
Perceptive Advisors and related parties report a 15.55% beneficial stake in Lyra Therapeutics. The Schedule 13D/A discloses ownership of 255,750 shares of Lyra common stock out of 1,644,454 shares outstanding as reported in the filing. Ownership is held collectively by Perceptive Advisors LLC and affiliated entities: Perceptive Life Sciences Master Fund, Ltd. (229,982 shares, 13.99%) and Perceptive LS (A), LLC (25,768 shares, 1.57%). The cover pages show shared voting and dispositive power over the reported shares and identify the source(s) of funds as stated in the filing. The filing provides a clear ownership breakdown and the percentage calculations based on the issuer's reported outstanding shares.
Lyra Therapeutics reported mixed clinical and financial results for the quarter. The company announced positive Phase 3 ENLIGHTEN 2 results for LYR-210, showing statistically significant improvement versus sham in the three-cardinal-symptom composite (3CS) at 24 weeks in patients without nasal polyps (treatment effect -1.13; p=0.0078), in the full population (-0.90; p=0.0209), and in SNOT-22 score (-8.7; p=0.0101). LYR-210 was generally well tolerated with no product-related serious adverse events.
On the financial side, Lyra had $29.8 million in cash and cash equivalents at June 30, 2025 and an accumulated deficit of approximately $420.8 million. Net loss was $7.4 million for the quarter and $16.0 million for the six months ended June 30, 2025. The company completed a June 2025 financing that raised $5.0 million gross ($4.3 million net) and sold shares under its shelf registration generating $26.7 million of proceeds (net). Following an earlier failed Phase 3 ENLIGHTEN 1 trial and related cost reductions (including a workforce reduction of 87 employees and impairment charges), management disclosed substantial doubt about its ability to continue as a going concern and has paused commercialization and certain development and manufacturing activities while pursuing strategic and cost-saving actions.